Fig. 1 · Structure

Documents & Downloads

Isepamicin

Cat. No. A11662 CAS 58152-03-7
Isepamicin (also Isepamycin) is an aminoglycoside antibiotic.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Isepamicin Research Summary

This section summarizes 2 in vitro studies of Isepamicin from 1 published reference. In vitro models include HEK293; MDCK.

Isepamicin In Vitro Studies

Isepamicin was assessed in HEK293 and MDCK cells using the MTT assay to determine nephrotoxicity. The reported result was >100 mM in each model. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Isepamicin nephrotoxicity assessment in HEK293

Cell-based study · HEK293 [1]

Isepamicin was added to designated wells containing HEK293 cells, and nephrotoxicity was assessed using the MTT assay. The reported result was >100 mM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nephrotoxicity of the antibiotics was determined by the MTT assayIC50 >100 mM[1]

Literature-Reported Treatment Conditions

Exposure duration
After 68 h of incubation, 20 μl MTT solution (4 mg/ml) was added to each well and the cells were further incubated for additional 4 h in the incubator.
Method
added into the designated wells
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Isepamicin

Evidence for Isepamicin as the sulfate form reported in the paper, not the free base/neutral form supplied as A11662; no salt equivalence, dose conversion or lot validation.

Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29, S31, S32); Table 2 (T2.h1, T2.h2, T2.r2)

Nephrotoxicity of the antibiotics was determined by the MTT assay: Nephrotoxicity of the antibiotics was determined by the MTT assay — Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29); Table 2 (T2.h1, T2.h2, T2.r2)

Isepamicin nephrotoxicity assessment in MDCK

Cell-based study · MDCK [1]

Isepamicin was added to designated wells containing MDCK cells, and nephrotoxicity was assessed using the MTT assay. The reported result was >100 mM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nephrotoxicity of the antibiotics was determined by the MTT assayIC50 >100 mM[1]

Literature-Reported Treatment Conditions

Exposure duration
After 68 h of incubation, 20 μl MTT solution (4 mg/ml) was added to each well and the cells were further incubated for additional 4 h in the incubator.
Method
added into the designated wells
Reported limits
Not stated in the sentences used: dose, vehicle, control.
Methods and source locations

Compound reported in the paper: Isepamicin

Evidence for Isepamicin as the sulfate form reported in the paper, not the free base/neutral form supplied as A11662; no salt equivalence, dose conversion or lot validation.

Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29, S31, S32); Table 2 (T2.h1, T2.h2, T2.r2)

Nephrotoxicity of the antibiotics was determined by the MTT assay: Nephrotoxicity of the antibiotics was determined by the MTT assay — Materials and Methods > Minimum Inhibitory Concentration Assay > Cytotoxicity Assay (S29); Table 2 (T2.h1, T2.h2, T2.r2)

Specifications

Manufacturer Adooq Bioscience
CAS Number 58152-03-7
Formula C22H43N5O12
Molecular Weight 569.6
Synonyms Isepamycin
SMILES
NC[C@H](O)C(N[C@H](C[C@@H]([C@H]([C@@H]1O)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)O)CN)N)[C@@H]1O[C@@H]3[C@@H]([C@H]([C@@](O)(CO3)C)NC)O)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Isepamicin Research References

  1. [1] Kong J, Wu ZX, Wei L, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol (2020). PMID: 32849365 DOI: 10.3389/fmicb.2020.01718 Source material

Added to your cart

View Cart Checkout
Loading...